Equities Analysts Offer Predictions for Evotec Q2 Earnings

Evotec SE (NASDAQ:EVO) – HC Wainwright lifted their Q2 2025 EPS estimates for Evotec in a note issued to investors on Wednesday, May 7th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.05) for the quarter, up from their prior forecast of ($0.06). The consensus estimate for Evotec’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec’s Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $0.02 EPS and FY2027 earnings at $0.44 EPS.

Separately, Deutsche Bank Aktiengesellschaft raised Evotec from a “sell” rating to a “hold” rating in a research report on Thursday, April 24th.

Evotec Trading Up 10.7%

Evotec stock opened at $4.33 on Monday. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. The firm’s fifty day moving average price is $3.61 and its 200 day moving average price is $4.17. Evotec has a 12-month low of $2.84 and a 12-month high of $5.68.

Hedge Funds Weigh In On Evotec

Large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new stake in shares of Evotec in the 4th quarter valued at approximately $27,000. CSS LLC IL bought a new stake in shares of Evotec in the 4th quarter worth approximately $50,000. Bank of America Corp DE increased its position in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares during the period. Lighthouse Investment Partners LLC acquired a new position in shares of Evotec during the fourth quarter valued at $166,000. Finally, ABC Arbitrage SA bought a new stake in Evotec in the 1st quarter valued at about $260,000. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.